AbbVie: U.S. FDA approval of JUVMO (tavapadon) as the first selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease.
https://finviz.com/stock?t=ABBV&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.